Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Laser Photonics

This article was originally published in The Gray Sheet

Executive Summary

Laser Photonics: Firm's AccuLase subsidiary files investigational device exemption application with FDA for use of its AccuLase excimer laser system to perform transmyocardial revascularization (TMR). Other firms investigating TMR include PLC Systems, which has a CO2 laser system; Eclipse Surgical Technologies, which uses a holmium laser; and CardioGenesis, which also uses a holmium laser. "We believe the excimer laser combines several critical components for minimizing thermal damage and therefore maximizing channel patency" and "will be the most effective, safest and easiest system to use for performing TMR," Laser Photonics states...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006434

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel